Hematology AdvisorNew COVID ‘Cicada’ Variant Is Spreading

📡 Surveillance / Emerging Signal
BA.3.2 carries approximately 70 to 75 mutations relative to prior lineages, prompting CDC and WHO surveillance attention. Symptom profile so far mirrors other circulating strains, with no severity signal reported. Vaccine effectiveness against this lineage remains undetermined.

Clinical Considerations

• The variant accounts for 3.7% of US wastewater samples as of mid-March, with XFG dominant at 53% and LF.7 at 10.3%.
• BA.3.2 has been detected in more than 20 countries, reaching up to 30% of cases in some regions.
• Symptoms overlap with prior strains, including some reports of severe pharyngitis (“razorblade throat”); no current evidence of increased severity.
• Mutation load relative to JN.1 raises theoretical concern about reduced vaccine match, though severe disease protection is expected to persist.

Practice Applications

• Recognize Cicada as a surveillance signal, not an established threat to vaccine effectiveness or severity.
• Monitor CDC MMWR and WHO updates as wastewater data and clinical surveillance mature.
• Counsel patients that current vaccines remain expected to protect against severe disease.
• Consider standard COVID testing protocols for symptomatic patients without changing thresholds based on variant alone.

Related Summaries